In Silico Study for Similar FDA Approved Drugs as Inhibitors of SARS-CoV-2 Spike and the Host Receptor Proteins

In Silico Study for Similar FDA Approved Drugs as Inhibitors of SARS-CoV-2 Spike and the Host Receptor Proteins

The severe acute respiratory syndrome coronavirus 2, known as COVID-19, has been hideously increased worldwide. The disease began in Wuhan, China, around December 2019, then spread to most countries. Social distancing is the best procedure to prevent infection. Screening the available database conta...

Full description

Bibliographic Details
Main Authors:	Israa Mohamed Shamkh, Dina Pratiwi, Hanaa S. Omar, Nour El-Houda A. Reyad
Format:	Article
Language:	English
Published:	Institute for Researches and Community Services Universitas Muhammadiyah Palangkaraya 2021-12-01
Series:	Journal of Molecular Docking
Subjects:	Molecular docking SARS-CoV-2 spike protein ACE2 receptor 14-ketostypodiol diacetate
Online Access:	http://journal.umpalangkaraya.ac.id/index.php/jmd/article/view/2213

Similar Items

Development of SARS-CoV-2 Inhibitors Using Molecular Docking Study with Different Coronavirus Spike Protein and ACE2
by: Israa Mohamed Shamkh, et al.
Published: (2021-06-01)

In Silico Discovery of GPCRs and GnRHRs as Novel Binding Receptors of SARS-CoV-2 Spike Protein Could Explain Neuroendocrine Disorders in COVID-19
by: Mahmoud Elkazzaz, et al.
Published: (2022-09-01)

<i>In silico</i> screening of chalcones and their derivatives as potential inhibitors of spike proteins and ACE2 enzymes for SARS-CoV-2 treatment
by: Thi Thu Hang Ta, et al.
Published: (2022-06-01)

Uncovering the impact of SARS-CoV2 spike protein variants on human receptors: A molecular dynamics docking and simulation approach
by: Muhammad Zaheer, et al.
Published: (2023-10-01)

Multifaceted membrane binding head of the SARS-CoV-2 spike protein
by: Anh Tran, et al.
Published: (2022-01-01)

Potential antiviral peptides targeting the SARS-CoV-2 spike protein
by: Ibrahim Khater, et al.
Published: (2022-12-01)

In Silico Analysis of Catechin, Galangin, and Hesperidin as Competitors of the SARS-CoV-2 Spike Protein
by: Astuti Kusumorini, et al.
Published: (2023-05-01)

<i>In Silico</i>, <i>In Vitro</i> and <i>In Cellulo</i> Models for Monitoring SARS-CoV-2 Spike/Human ACE2 Complex, Viral Entry and Cell Fusion
by: Delphine Lapaillerie, et al.
Published: (2021-02-01)

Inhibitory activity of FDA-approved drugs cetilistat, abiraterone, diiodohydroxyquinoline, bexarotene, remdesivir, and hydroxychloroquine on COVID-19 main protease and human ACE2 receptor: A comparative in silico approach
by: Nahid Shahabadi, et al.
Published: (2021-01-01)

In silico Identification of Characteristics Spike Glycoprotein of SARS-CoV-2 in the Development Novel Candidates for COVID-19 Infectious Diseases
by: Taufik Muhammad Fakih, et al.
Published: (2020-08-01)

SARS-CoV-2 host cell entry: an in silico investigation of potential inhibitory roles of terpenoids
by: Gideon A. Gyebi, et al.
Published: (2021-08-01)

In silico Screening of Natural Compounds as Potential Inhibitors of SARS-CoV-2 Main Protease and Spike RBD: Targets for COVID-19
by: Divya M. Teli, et al.
Published: (2021-01-01)

Proteomic Approach for Comparative Analysis of the Spike Protein of SARS-CoV-2 Omicron (B.1.1.529) Variant and Other Pango Lineages
by: Mukul Jain, et al.
Published: (2022-10-01)

Interference of Polydatin/Resveratrol in the ACE2:Spike Recognition during COVID-19 Infection. A Focus on Their Potential Mechanism of Action through Computational and Biochemical Assays
by: Fulvio Perrella, et al.
Published: (2021-07-01)

SARS-CoV-2 Spike Protein Activates Human Lung Macrophages
by: Francesco Palestra, et al.
Published: (2023-02-01)

1,4-diazanium-bicyclo[2.2.2]octane diacetate: As an effective, new and reusable media for the synthesis of 14-aryl-14H-dibenzo [a,j]xanthenes
by: Leila Zare Fekri, et al.
Published: (2016-05-01)

Mutations of the SARS-CoV-2 Spike Glycoprotein Detected in Cats and Their Effect on Its Structure and Function
by: Mervat E. Hamdy, et al.
Published: (2022-06-01)

The Utilization of Nutraceuticals and Phytochemical Compounds to Inhibit The Interaction of Spike-protein SARS-CoV-2 Virus and ACE-2 Receptor for COVID-19 Therapy (Literature Review)
by: David Ferdinand, et al.
Published: (2023-06-01)

In-silico study for the identification of potential destabilizers between the spike protein of SARS-CoV-2 and human ACE-2
by: Jeffry Medina-Barandica, et al.
Published: (2023-01-01)

Phenylation of aminoindazole derivatives
by: Abdellah Miloudi, et al.
Published: (2017-12-01)

Discovery of a new generation of angiotensin receptor blocking drugs: Receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2
by: Harry Ridgway, et al.
Published: (2022-01-01)

The Development of Pharmacophore Models for the Search of New Natural Inhibitors of SARS-CoV-2 Spike RBD–ACE2 Binding Interface
by: Valentin A. Semenov, et al.
Published: (2022-12-01)

Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor
by: Tamim Ahsan, et al.
Published: (2021-07-01)

Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction
by: Shijulal Nelson-Sathi, et al.
Published: (2022-01-01)

Binding affinity between coronavirus spike protein and human ACE2 receptor
by: Marcus Ho-Hin Shum, et al.
Published: (2024-12-01)

Analysis of SARS-CoV-2 Spike Protein as The Key Target in the Development of Antiviral Candidates for COVID-19 through Computational Study
by: Taufik Muhammad Fakih, et al.
Published: (2021-12-01)

SARS-CoV-2 omicron spike simulations: broad antibody escape, weakened ACE2 binding, and modest furin cleavage
by: M. Zaki Jawaid, et al.
Published: (2023-10-01)

In Silico computational screening of Kabasura Kudineer - Official Siddha Formulation and JACOM against SARS-CoV-2 spike protein
by: Gangarapu Kiran, et al.
Published: (2022-01-01)

A Suitable Membrane Distance Regulated by the RBD_ACE2 Interaction is Critical for SARS‐CoV‐2 Spike‐Mediated Viral Invasion
by: Mengdan Wu, et al.
Published: (2023-10-01)

Investigation of Interaction between the Spike Protein of SARS-CoV-2 and ACE2-Expressing Cells Using an In Vitro Cell Capturing System
by: Yuning Shang, et al.
Published: (2021-08-01)

Triterpene Derivatives as Potential Inhibitors of the RBD Spike Protein from SARS-CoV-2: An In Silico Approach
by: Mayra Avelar, et al.
Published: (2023-03-01)

Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes
by: Debashree Chatterjee, et al.
Published: (2022-01-01)

Computational optimization of angiotensin-converting enzyme 2 for SARS-CoV-2 Spike molecular recognition
by: Lorenzo Di Rienzo, et al.
Published: (2021-01-01)

Recombinant SARS-CoV-2 Spike Protein Stimulates Secretion of Chymase, Tryptase, and IL-1β from Human Mast Cells, Augmented by IL-33
by: Irene Tsilioni, et al.
Published: (2023-05-01)

Biochemical Characterization of SARS-CoV-2 Spike RBD Mutations and Their Impact on ACE2 Receptor Binding
by: Abdullah Hoter, et al.
Published: (2022-05-01)

The inhibitory effect of vitamins on O micron virus via targeting the ACE2 receptor. In silico analysis
by: Khadidja BELKHEIR, et al.
Published: (2024-02-01)

Direct Inhibition of SARS-CoV-2 Spike Protein by Peracetic Acid
by: Yuichiro Yamamoto, et al.
Published: (2022-12-01)

SARS CoV-2 Nucleoprotein Enhances the Infectivity of Lentiviral Spike Particles
by: Tarun Mishra, et al.
Published: (2021-04-01)

Repositioning of Ligands That Target the Spike Glycoprotein as Potential Drugs for SARS-CoV-2 in an In Silico Study
by: Gema Lizbeth Ramírez-Salinas, et al.
Published: (2020-11-01)

Lutein, zeaxanthin and meso-zeaxanthin content of eggs laid by hens supplemented with free and esterified xanthophylls
by: John M. Nolan, et al.
Published: (2016-01-01)